Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
Rhian M. Touyz, Joerg Herrmann
npj Precision Oncology (2018) Vol. 2, Iss. 1
Open Access | Times Cited: 171

Showing 26-50 of 171 citing articles:

Use of new and emerging cancer drugs: what the cardiologist needs to know
Iacopo Fabiani, Michela Chianca, Alberto Aimo, et al.
European Heart Journal (2024) Vol. 45, Iss. 22, pp. 1971-1987
Closed Access | Times Cited: 7
Cardiovascular health of patients with cancer: Challenges abound
Jeffrey Shi Kai Chan, Raymond Chan, Yan Hiu Athena Lee, et al.
Trends in Cardiovascular Medicine (2024)
Open Access | Times Cited: 6
Preventive Cardio-Oncology: The Time Has Come
Sherry‐Ann Brown
Frontiers in Cardiovascular Medicine (2020) Vol. 6
Open Access | Times Cited: 42
Cardiotoxicity of chemotherapy and targeted agents.
Todd William Mudd, Mansoor Khalid, Achuta Kumar Guddati
PubMed (2021) Vol. 11, Iss. 4, pp. 1132-1147
Closed Access | Times Cited: 36
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
HSP47 in human diseases: Navigating pathophysiology, diagnosis and therapy
Essak S. Khan, Tobias Däinghaus
Clinical and Translational Medicine (2024) Vol. 14, Iss. 8
Open Access | Times Cited: 5
Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy
Masahiro Nishi, Pingyuan Wang, Paul M. Hwang
Arteriosclerosis Thrombosis and Vascular Biology (2021) Vol. 41, Iss. 11, pp. 2648-2660
Open Access | Times Cited: 29
Management of Acute Coronary Syndrome in Cancer Patients: It’s High Time We Dealt with It
Fabiana Lucà, Iris Parrini, Maurizio Giuseppe Abrignani, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 7, pp. 1792-1792
Open Access | Times Cited: 21
Genetics of cancer therapy-associated cardiotoxicity
Yuri Kim, Jonathan G. Seidman, Christine E. Seidman
Journal of Molecular and Cellular Cardiology (2022) Vol. 167, pp. 85-91
Open Access | Times Cited: 19
Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease
Rong Jiang, Lian Lou, Wen Shi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10177-10177
Open Access | Times Cited: 4
Comprehensive review of non-invasive treatment related cardiovascular toxicity in breast cancer
C Li, Huijuan Dai, Xinning Guo, et al.
iScience (2025) Vol. 28, Iss. 4, pp. 111759-111759
Closed Access
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
Qingjian He, Junling Lin, Chaohua Mo, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV
Federico Corti, Filippo Locri, Flavia Plastino, et al.
Translational Vision Science & Technology (2025) Vol. 14, Iss. 1, pp. 10-10
Open Access
Sorafenib-induced cardiovascular toxicity: a cause for concern
Zheng Deng, Shuang Xiao, Yingying He, et al.
Chemico-Biological Interactions (2025), pp. 111388-111388
Closed Access
Biomarkers for cancer therapy-related cardiovascular toxicity
Jiaxin Song, Shuqin Liu, Xiaohui Shi, et al.
International review of cell and molecular biology (2025)
Closed Access
The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury
Chih-Jen Liu, Lu‐Kai Wang, Fu‐Ming Tsai
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 176-176
Open Access
Overview of Oncology: Drug-Induced Cardiac Toxicity
Nilima Rajpal Kundnani, V Vieira Passini, Iulia Stefania Carlogea, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 709-709
Open Access
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction
Kei Kunimasa, Toru Oka, Satoshi Hara, et al.
Lung Cancer (2020) Vol. 153, pp. 186-192
Closed Access | Times Cited: 30
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
Αlexandros Briasoulis, Angeliki Chasouraki, Alexandros Sianis, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 3, pp. 66-66
Open Access | Times Cited: 18
Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells
Nemany A.N. Hanafy, Eman A. Eltonouby, Elsayed I. Salim, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3548-3548
Open Access | Times Cited: 10
Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies
Giacomo Tini, Giuliano Tocci, Allegra Battistoni, et al.
Current Heart Failure Reports (2023) Vol. 20, Iss. 1, pp. 56-62
Open Access | Times Cited: 9
Interferon‐regulatory factor‐1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14‐3‐3γ axis
Xuanying Chen, Meng‐Qi Xie, Weilin Huang, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 2, pp. 986-1000
Open Access | Times Cited: 3
Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells
Chrysa Koukorava, Katie Ahmed, Shrouq Almaghrabi, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 3
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Darya Zibrova, Thomas Ernst, Andreas Hochhaus, et al.
Molecular and Cellular Biochemistry (2024) Vol. 480, Iss. 3, pp. 1627-1643
Open Access | Times Cited: 3
Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system
Qiong Jie, Yuanyuan Li, Jing Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3

Scroll to top